Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zanubrutinib + R-CHOP in IVLBCL
NCT04899570Phase 2Unknown
- Sponsor
- Peking Union Medical College Hospital
- Start
- Apr 2021
- Primary completion
- Apr 2023
- Modality
- Fragment-Derived Small Molecules, Reversible Covalent Inhibitors, Bivalent/Multivalent Binders
- Countries
- 1
01
Overview
A Phase 2 trial of zanubrutinib in intravascular large B-cell lymphoma (IVLBCL), sponsored by Peking Union Medical College Hospital. Status: unknown.
02
Drugs
zanubrutinib
03
Conditions
intravascular large B-cell lymphoma (IVLBCL)
Beyond the preview
Go deeper on NCT04899570.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04899570.